Home > Dermatology > AAD 2022 > Psoriasis: State of the Art > Long-term psoriasis treatment with bimekizumab results in maintained efficacy

Long-term psoriasis treatment with bimekizumab results in maintained efficacy

Presented By
Prof. Kenneth Gordon, Medical College of Wisconsin, USA
Conference
AAD 2022
More than 80% of patients with psoriasis preserved their Psoriasis Area and Severity Index (PASI)100 response over 2 years of treatment with bimekizumab in a pooled analysis of several phase 3 trials. The safety results over 48 weeks were consistent with previous shorter-term results. Dual IL-17A/F inhibition with bimekizumab has demonstrated a meaningful benefit for patients with moderate-to-severe plaque psoriasis in various phase 3 clinical trials [1–3]. Its high efficacy is explained by its mechanisms of action (see Figure) [4]. “What happens long-term becomes the critical question,” stressed Prof. Kenneth Gordon (Medical College of Wisconsin, WI, USA). Therefore, a pooled analysis was performed of 5 phase 3 and 3b trials to assess the long-term efficacy and safety of the drug over 2 years [5]. During the initial phase 3 periods, 62.4% (n=850) of the study population on bimekizumab reached PASI100. The 86.9% of responders with a PASI of at least 90 at ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on